Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2/3 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Astrocytoma 2Recurrence 1Oligodendroglioma 1

Interventions

Temozolomide 8Lomustine 4vocimagene amiretrorepvec 2Radiation 2veliparib 1tinostamustine 1regorafenib 1carbon-11 acetate 1antisecretory factor 1Sunitinib 1Standard of Care 1Radiotherapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1GDC-0084 1Flucytosine 1Etoposide 1Drug Therapy 1Disulfiram 1Dianhydrogalactitol 1DNA 1Copper 1Carbon-11 1Bevacizumab 1Alkylating Agents 1AZD1390 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Glioblastoma × vocimagene amiretrorepvec × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated
403 enrolled
CNS

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡